- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Adaptive Approach to Clinical Trials
The design of clinical trials and the volume of pharmacogenomics data being generated present challenges to the development and success of future treatment options.
Irwin W. Tischler, DO, suggests that an adaptive approach to clinical trial design can accelerate the development of new agents. He explains that having the capability to modify the design of a trial based upon preliminary results, on an as-you-go basis, may help speed the clinical trial process. For example, based on initial data, the dose of a drug used might be changed during the course of the trial, or the patient population might be modified to include patients who would benefit most.
Dr Tischler adds that pharmacogenetic testing is associated with financial challenges. He explains that testing often involves more than 200 genetic markers; however, only 20 genetic markers are presently actionable. Thus, large amounts of money are being invested on information that is not clinically relevant.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
